PROSPECTUS SUMMARY
This summary highlights certain information about us, the Private Placement (as defined below) and selected information contained elsewhere in or
incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of our company, you should read
and consider carefully the more detailed information included or incorporated by reference in this prospectus and any applicable prospectus supplement, including the factors described under the heading Risk Factors on page 4 of this
prospectus, as well as the information incorporated herein by reference, before making an investment decision.
Unless the context indicates
otherwise, references in this prospectus to Harpoon, Harpoon Therapeutics, the Company, we, us, our and similar references refer to Harpoon Therapeutics, Inc.
Company Overview
We are a clinical-stage immunotherapy
company developing a novel class of T cell engagers that harness the power of the bodys immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patients own T cells
to kill target cells that express specific proteins, or antigens, carried by the target cells. Using our proprietary Tri-specific T cell Activating Construct (TriTAC) platform, we are developing a pipeline of
novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. We have also developed a proprietary ProTriTAC platform, which applies a prodrug concept to our TriTAC platform to create a therapeutic T cell engager
that remains inactive until it reaches the tumor.
Company Information
We were incorporated as a Delaware corporation in March 2015. Our principal executive offices are located at 611 Gateway Boulevard, Suite 400, South San
Francisco, California 94080, and our telephone number is (650) 443-7400. Our website address is www.harpoontx.com. The information contained on, or that can be accessed through, our website is not
incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus.
Harpoon Therapeutics, Harpoon, the Harpoon logo, TriTAC, ProTriTAC and our other registered or common law trademarks, trade names or
service marks appearing in this prospectus are owned by us. This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus,
including logos, artwork and other visual displays, generally appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the
fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies trade names or trademarks to imply a relationship with, or
endorsement or sponsorship of us by, any other companies.
We are an emerging growth company, as defined in the Jumpstart Our Business
Startups Act of 2012. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive compensation.
Private Placement
On October 22, 2023, we entered
into a Securities Purchase Agreement, or the Purchase Agreement, with the selling stockholders named in this prospectus, pursuant to which we issued and sold the following securities to